SCHEMBL8480044

SCHEMBL8480044

CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N(CCOC(C)=O)CCN(CC)CC)ccc3OCC)nc12

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.75
PDE5A O76074 16/20 0.68
KMT2A Q03164 1/20 0.64
KDM4E B2RXH2 1/20 0.62
PDE6C P51160 2/20 0.61
PDE3B Q13370 2/20 0.59
PDE3A Q14432 2/20 0.59
PDE2A O00408 1/20 0.59
ABCC4 O15439 1/20 0.59
ABCC5 O15440 1/20 0.59
PDE6D O43924 1/20 0.59
PDE8A O60658 1/20 0.59
PDE9A O76083 1/20 0.59
ABCB11 O95342 1/20 0.59
CYP3A4 P08684 1/20 0.59
HTR1A P08908 1/20 0.59
PDE6A P16499 1/20 0.59
PDE6G P18545 1/20 0.59
PDE4A P27815 1/20 0.59
ADORA2A P29274 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8487516 0.97 POLB (0.72) POLBPDE5AKMT2AKDM4EPDE6C
SCHEMBL13990475 0.96 POLB (0.82) POLBPDE5AKMT2AKDM4EPDE6C
SCHEMBL13990484 0.95 POLB (0.72) POLBPDE5AKMT2AKDM4EPDE6C
SCHEMBL13065925 0.92 POLB (0.81) POLBPDE5AKMT2AKDM4EPDE6C
SCHEMBL8503688 0.92 POLB (0.78) POLBPDE5AKMT2AKDM4EPDE6C
SCHEMBL13990469 0.92 POLB (0.74) POLBPDE5AKMT2AKDM4EPDE6C
SCHEMBL13990482 0.91 POLB (0.91) POLBPDE5AKMT2AKDM4EPDE6C
SCHEMBL8490596 0.90 POLB (0.80) POLBPDE5AKMT2AKDM4EPDE6C
SCHEMBL13065809 0.90 POLB (0.72) POLBPDE5AKMT2AKDM4EPDE6C
SCHEMBL13065815 0.90 POLB (0.70) POLBPDE5AKMT2AKDM4EPDE6C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2253632-B1 Pyrazolopyramidinone derivatives, their preparation and their use TOPHARMAN SHANGHAI CO LTD (CN) 2012-05-23 EP disclosed
EP-2253632-A1 Pyrazolopyramidinone derivatives, their preparation and their use Topharman Shanghai Co., Ltd. (CN) 2010-11-24 EP disclosed
US-20080318949-A1 Pyrazolopyrimidinone Derivatives, Their Preparation And Their Use TOPHARMAN SHANGHAI CO., LTD (CN) 2008-12-25 US disclosed
US-20080318949-A1 Pyrazolopyrimidinone Derivatives, Their Preparation And Their Use TOPHARMAN SHANGHAI CO., LTD (CN) 2008-12-25 US disclosed
EP-1961753-A1 PYRAZOLOPYRIMIDINONE DERIVATIVES, THEIR PREPARATION AND THEIR USE Topharman Shanghai Co., Ltd. (CN) 2008-08-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318949-A1 Pyrazolopyrimidinone Derivatives, Their Preparation And Their Use PDE5A, PDE3A, PDE3B POLB 2222/4885PDE5A 1/4885KMT2A 3136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.